Trial Profile
A Phase I Trial of BBR 2778 [pixantrone] in Combination With Cytarabine, Methylprednisolone and Cisplatin in the Treatment of Patients With Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Cytarabine (Primary) ; Methylprednisolone (Primary) ; Pixantrone (Primary)
- Indications Diffuse large B cell lymphoma; Follicular lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Adverse reactions
- 04 Oct 2005 New trial record.